dcc-3009

DCC-3009 is a next-generation, orally administered small molecule inhibitor developed to target the broad spectrum of primary and secondary drug-resistant mutations in the KIT gene, including exons 9, 11, 13, 14, 17, and 18. It is designed using a proprietary switch-control platform to potently inhibit both primary KIT mutations and secondary resistance mutations that commonly arise in gastrointestinal stromal tumors (GIST). Preclinical studies have demonstrated that DCC-3009 achieves high free drug concentrations in plasma and effectively inhibits KIT phosphorylation across multiple mutant forms. The drug has shown tumor regression activity in preclinical models of GIST with various resistant KIT mutations. Its optimized pharmaceutical properties support oral administration with low brain penetration. DCC-3009 is being developed primarily for the treatment of GIST by Deciphera Pharmaceuticals (now a subsidiary of Ono Pharmaceutical) and is currently undergoing Phase I/II clinical trials for this indication[1][2][3][4][5].